Patents by Inventor Elaine F. REED

Elaine F. REED has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-HLA MARKERS OF TRANSPLANT REJECTION
    Publication number: 20220244271
    Abstract: The present invention generally relates to transplantation rejection. In particular, the present invention provides compositions, kits, assays, and methods of determining if a subject has allograft rejection, or an increased risk of developing rejection after transplantation, and methods of treatment thereof.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 4, 2022
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Elaine F. REED, Michelle HICKEY, Carrie L. BUTLER, David W. GJERTSON
  • Protein biomarkers for immune assessment and prediction of transplant rejection
    Patent number: 10451636
    Abstract: The invention provides a method for screening for and detection of solid organ graft rejection in a subject that comprises assaying a patient sample of plasma, serum or blood from the subject for a protein marker identified herein. An elevated or reduced amount of marker present in the patient sample compared to a control sample is indicative of rejection, and identifies subjects in need of biopsy or modified treatment. The method can be used to screen for patients in danger of transplant rejection without having to undergo more costly, risky and invasive biopsy procedures.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: October 22, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Elaine F. Reed, Hans Albin Gritsch, Jeffrey Lorne Veale
  • PROTEIN BIOMARKERS FOR IMMUNE ASSESSMENT AND PREDICTION OF TRANSPLANT REJECTION
    Publication number: 20170030928
    Abstract: The invention provides a method for screening for and detection of solid organ graft rejection in a subject that comprises assaying a patient sample of plasma, serum or blood from the subject for a protein marker identified herein. An elevated or reduced amount of marker present in the patient sample compared to a control sample is indicative of rejection, and identifies subjects in need of biopsy or modified treatment. The method can be used to screen for patients in danger of transplant rejection without having to undergo more costly, risky and invasive biopsy procedures.
    Type: Application
    Filed: April 9, 2015
    Publication date: February 2, 2017
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Elaine F. REED, Hans Albin GRITSCH, Jeffrey Lorne VEALE